These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31452794)

  • 21. Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer.
    Huang N; Wu Z; Hong H; Wang X; Yang F; Li H
    Mol Med Rep; 2019 Jun; 19(6):4761-4769. PubMed ID: 30957190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of key candidate genes, pathways and related prognostic values in ER-negative/HER2-negative breast cancer by bioinformatics analysis.
    Shao N; Yuan K; Zhang Y; Yun Cheang T; Li J; Lin Y
    J BUON; 2018; 23(4):891-901. PubMed ID: 30358191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expressions and prognostic values of the
    Liu ZL; Bi XW; Liu PP; Lei DX; Wang Y; Li ZM; Jiang WQ; Xia Y
    Cancer Manag Res; 2018; 10():3521-3532. PubMed ID: 30271201
    [No Abstract]   [Full Text] [Related]  

  • 24. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
    Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
    Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioinformatics analysis of potential therapeutic targets among
    Chen WX; Lou M; Cheng L; Qian Q; Xu LY; Sun L; Zhu YL; Dai H
    Oncol Lett; 2019 Dec; 18(6):6017-6025. PubMed ID: 31788076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer.
    Xu H; Bai X; Yu S; Liu Q; Pestell RG; Wu K
    Chin J Cancer Res; 2018 Jun; 30(3):351-363. PubMed ID: 30046229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer.
    Lin X; Liu J; Hu SF; Hu X
    Cancer Manag Res; 2019; 11():2203-2214. PubMed ID: 31114314
    [No Abstract]   [Full Text] [Related]  

  • 29. Elevated FKBP52 expression indicates a poor outcome in patients with breast cancer.
    Hong C; Li T; Zhang F; Wu X; Chen X; Cui X; Zhang G; Cui Y
    Oncol Lett; 2017 Nov; 14(5):5379-5385. PubMed ID: 29113172
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitamin D receptor (
    Nam SE; Jin T; Park KS; Saindane M; Noh WC; Yoo YB; Park WS; Yun IJ
    Ann Surg Treat Res; 2022 Oct; 103(4):183-194. PubMed ID: 36304189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.
    Sicking I; Rommens K; Battista MJ; Böhm D; Gebhard S; Lebrecht A; Cotarelo C; Hoffmann G; Hengstler JG; Schmidt M
    BMC Cancer; 2014 Dec; 14():952. PubMed ID: 25511800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A meta‑ and bioinformatics analysis of maspin expression levels influencing the prognosis of patients with breast cancer.
    Shi S; Zhang ZG; Sang YZ; Sun J; Ma HY
    Oncol Lett; 2024 Apr; 27(4):173. PubMed ID: 38464336
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer.
    Jing X; Liang H; Hao C; Yang X; Cui X
    Oncol Rep; 2019 Feb; 41(2):801-810. PubMed ID: 30483806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
    Hou MF; Chen PM; Chu PY
    BMC Cancer; 2018 Feb; 18(1):219. PubMed ID: 29471794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enabled homolog shown to be a potential biomarker and prognostic indicator for breast cancer by bioinformatics analysis.
    Li QL; Su YL; Zeng M; Shen WX
    Clin Invest Med; 2019 Jan; 41(4):E186-E195. PubMed ID: 30737978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression and clinical significance of secretory leukocyte proteinase inhibitor (SLPI) in mammary carcinoma using bioinformatics analysis.
    Xie W; Zhang H; Qin S; Zhang J; Fan X; Yin Y; Liang R; Long H; Yi W; Fu D; Ma C; Lv M; Yu F
    Gene; 2019 Dec; 720():144088. PubMed ID: 31476404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An integrated bioinformatics analysis of potential therapeutic targets among matrix metalloproteinases in breast cancer.
    Xia H; Yu W; Liu M; Li H; Pang W; Wang L; Zhang Y
    Oncol Lett; 2019 Sep; 18(3):2985-2994. PubMed ID: 31452777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients.
    Song GD; Sun Y; Shen H; Li W
    Tumour Biol; 2015 Jun; 36(6):4167-73. PubMed ID: 25592378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deficiency of
    Yan L; Yin H; Mi Y; Wu Y; Zheng Y
    Front Cell Dev Biol; 2023; 11():1084245. PubMed ID: 37228654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.